BackTable / ENT / Podcast / Episode #245
Understanding Keynote 689: Immunotherapy for Head & Neck Cancer
with Dr. Dylan Roden and Dr. Ravi Uppaluri
While the standard for adjuvant head and neck cancer treatment hasn't changed since 2004, a new trial using perioperative pembrolizumab is forcing clinicians to rethink their entire workflow, starting with diagnosis. In this episode of the BackTable Podcast, head and neck surgical oncologist Dr. Adam Luginbuhl is joined by colleagues Dr. Dylan Roden and Dr. Ravindra Uppaluri to discuss the implementation and implications of the Keynote-689 trial, which introduced neoadjuvant and adjuvant immunotherapy for locally advanced head and neck cancer.
Be part of the conversation. Put your sponsored messaging on this episode. Learn how.

BackTable, LLC (Producer). (2025, October 28). Ep. 245 – Understanding Keynote 689: Immunotherapy for Head & Neck Cancer [Audio podcast]. Retrieved from https://www.backtable.com
Stay Up To Date
Follow:
Subscribe:
Sign Up:
Podcast Contributors
Synopsis
The doctors discuss the trial details, FDA approval, and practical challenges of integrating this new paradigm into clinical practice. The conversation covers critical points such as the necessity of CPS score testing, timely drug administration, patient monitoring, and the importance of collaboration among multidisciplinary teams.
Timestamps
00:00 - Introduction
02:18 - Keynote-689 Trial Explained
04:42 - Implementation Challenges and Strategies
06:40 - Practical Considerations for CPS Testing
13:59 - Case Studies and Real-World Applications
30:48 - Future Directions and Final Thoughts
Resources
Keynote-689
https://www.nejm.org/doi/full/10.1056/NEJMoa2415434
2004 Cisplatin Phase III Trial
https://www.nejm.org/doi/full/10.1056/NEJMoa032646
The Materials available on BackTable are for informational and educational purposes only and are not a substitute for the professional judgment of a healthcare professional in diagnosing and treating patients. The opinions expressed by participants of the BackTable Podcast belong solely to the participants, and do not necessarily reflect the views of BackTable.










